Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Research & Development (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Research & Development for 11 consecutive years, with $11.7 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 9.01% to $11.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.1 million through Dec 2025, down 24.06% year-over-year, with the annual reading at $49.1 million for FY2025, 24.06% down from the prior year.
  • Research & Development hit $11.7 million in Q4 2025 for Seres Therapeutics, down from $12.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $46.8 million in Q2 2023 to a low of -$17.0 million in Q4 2022.
  • Historically, Research & Development has averaged $25.2 million across 5 years, with a median of $24.1 million in 2023.
  • Biggest five-year swings in Research & Development: tumbled 146.39% in 2022 and later skyrocketed 235.16% in 2023.
  • Year by year, Research & Development stood at $36.8 million in 2021, then tumbled by 146.39% to -$17.0 million in 2022, then surged by 235.16% to $23.0 million in 2023, then plummeted by 44.27% to $12.8 million in 2024, then dropped by 9.01% to $11.7 million in 2025.
  • Business Quant data shows Research & Development for MCRB at $11.7 million in Q4 2025, $12.6 million in Q3 2025, and $12.9 million in Q2 2025.